Genprex Competitors

Prothena (NASDAQ:PRTA) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.

Volatility & Risk

Prothena has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Genprex has a beta of -0.57, indicating that its stock price is 157% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Prothena and Genprex, as reported by MarketBeat.

Prothena currently has a consensus target price of $28.2857, suggesting a potential upside of 26.73%. Genprex has a consensus target price of $6.00, suggesting a potential upside of 16.28%. Given Prothena's higher probable upside, equities research analysts plainly believe Prothena is more favorable than Genprex.

Valuation & Earnings

This table compares Prothena and Genprex's revenue, earnings per share and valuation.

Genprex has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 12.5% of Genprex shares are owned by institutional investors. 30.4% of Prothena shares are owned by insiders. Comparatively, 13.1% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Prothena and Genprex's net margins, return on equity and return on assets.

Summary

Prothena beats Genprex on 8 of the 12 factors compared between the two stocks.

Genprex (NASDAQ:GNPX) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Genprex has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Genprex and Phibro Animal Health, as provided by MarketBeat.

Genprex currently has a consensus target price of $6.00, suggesting a potential upside of 16.28%. Phibro Animal Health has a consensus target price of $21.50, suggesting a potential downside of 0.32%. Given Genprex's stronger consensus rating and higher probable upside, analysts clearly believe Genprex is more favorable than Phibro Animal Health.

Valuation and Earnings

This table compares Genprex and Phibro Animal Health's revenue, earnings per share (EPS) and valuation.

Phibro Animal Health has higher revenue and earnings than Genprex. Genprex is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.5% of Genprex shares are owned by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are owned by institutional investors. 13.1% of Genprex shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genprex and Phibro Animal Health's net margins, return on equity and return on assets.

Summary

Phibro Animal Health beats Genprex on 10 of the 13 factors compared between the two stocks.

Genprex (NASDAQ:GNPX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Genprex has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Genprex and Lexicon Pharmaceuticals, as provided by MarketBeat.

Genprex currently has a consensus target price of $6.00, suggesting a potential upside of 16.28%. Lexicon Pharmaceuticals has a consensus target price of $9.40, suggesting a potential upside of 30.74%. Given Lexicon Pharmaceuticals' higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Genprex.

Valuation and Earnings

This table compares Genprex and Lexicon Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Lexicon Pharmaceuticals has higher revenue and earnings than Genprex. Genprex is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.5% of Genprex shares are owned by institutional investors. Comparatively, 84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. 13.1% of Genprex shares are owned by company insiders. Comparatively, 6.4% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genprex and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Lexicon Pharmaceuticals beats Genprex on 8 of the 13 factors compared between the two stocks.

Genprex (NASDAQ:GNPX) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Genprex has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Genprex and ESSA Pharma, as provided by MarketBeat.

Genprex currently has a consensus target price of $6.00, suggesting a potential upside of 16.28%. ESSA Pharma has a consensus target price of $23.50, suggesting a potential downside of 13.25%. Given Genprex's higher probable upside, analysts clearly believe Genprex is more favorable than ESSA Pharma.

Valuation and Earnings

This table compares Genprex and ESSA Pharma's revenue, earnings per share (EPS) and valuation.

ESSA Pharma is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.5% of Genprex shares are owned by institutional investors. Comparatively, 63.4% of ESSA Pharma shares are owned by institutional investors. 13.1% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genprex and ESSA Pharma's net margins, return on equity and return on assets.

Genprex (NASDAQ:GNPX) and Radius Health (NASDAQ:RDUS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Genprex has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, Radius Health has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Genprex and Radius Health, as provided by MarketBeat.

Genprex currently has a consensus target price of $6.00, suggesting a potential upside of 16.28%. Radius Health has a consensus target price of $23.3333, suggesting a potential upside of 25.38%. Given Radius Health's higher probable upside, analysts clearly believe Radius Health is more favorable than Genprex.

Valuation and Earnings

This table compares Genprex and Radius Health's revenue, earnings per share (EPS) and valuation.

Genprex has higher earnings, but lower revenue than Radius Health. Genprex is trading at a lower price-to-earnings ratio than Radius Health, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.5% of Genprex shares are owned by institutional investors. 13.1% of Genprex shares are owned by company insiders. Comparatively, 2.9% of Radius Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genprex and Radius Health's net margins, return on equity and return on assets.

Summary

Genprex beats Radius Health on 7 of the 13 factors compared between the two stocks.

Genprex (NASDAQ:GNPX) and Five Prime Therapeutics (NASDAQ:FPRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Genprex has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, meaning that its stock price is 340% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Genprex and Five Prime Therapeutics, as provided by MarketBeat.

Genprex currently has a consensus target price of $6.00, suggesting a potential upside of 16.28%. Five Prime Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 12.46%. Given Genprex's stronger consensus rating and higher probable upside, analysts clearly believe Genprex is more favorable than Five Prime Therapeutics.

Valuation and Earnings

This table compares Genprex and Five Prime Therapeutics' revenue, earnings per share (EPS) and valuation.

Genprex has higher earnings, but lower revenue than Five Prime Therapeutics. Genprex is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.5% of Genprex shares are owned by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are owned by institutional investors. 13.1% of Genprex shares are owned by company insiders. Comparatively, 6.4% of Five Prime Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genprex and Five Prime Therapeutics' net margins, return on equity and return on assets.

Summary

Five Prime Therapeutics beats Genprex on 7 of the 13 factors compared between the two stocks.